InspireMD, Inc. has 18 Schedule 13D or 13G filings on record since 2025-08-06. 9 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Marshall Wace, Llp | 9.99% | 28,103,699 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Nantahala Capital Management, LLC | 9.99% | 4,819,647 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Rosalind Advisors, Inc. | 9.2% | 10,987,104 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
| Michael A. Lawless | 8.6% | 3,614,731 | SCHEDULE 13D, 2025-10-29 | 2025-06-26 |
| Aberdeen Group plc | 7.49% | 3,173,364 | SCHEDULE 13G/A, 2026-02-02 | 2025-12-31 |
| Orbimed Advisors LLC | 7.4% | 3,133,405 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Parkman Healthcare Partners LLC | 5.8% | 2,440,633 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| Nantahala Capital Partners Limited Partnership | 5.68% | 2,418,016 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Marvin Slosman | 5.18% | 2,556,760 | SCHEDULE 13D, 2026-04-24 | 2026-01-22 |
| Velan Capital Master Fund LP | 4.99% | 2,347,779 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Craig Shore | 3.5% | 1,484,505 | SCHEDULE 13D/A, 2025-10-29 | 2025-06-26 |
Purpose of Transaction (Item 4)
Michael A. Lawless
Item 3 above is hereby incorporated into this Item 4 by reference. The Reporting Person serves as an executive officer of the Issuer and, in such capacity, may be involved in reviewing transactions involving the Issuer and may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. As of the date hereof, the Reporting Person in his individual capacity does not have any present plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D. The Reporting Person may, at any time and from time to time, (i) review or reconsider his position in the Issuer or change his purpose or formulate plans or proposals with respect thereto or (ii) propose or consider one or more of the actions described in clauses (a) through (j) of Item 4 to Schedule 13D. From time to time, the Reporting Person may also acquire beneficial ownership of additional Shares or other securities of the Issuer as compensation from the Issuer, by purchase or otherwise, including, including, but not limited to, awards of restricted Shares, options to purchase Shares, and restricted stock units for Shares, or dispose of some or all of the Shares beneficially owned by the Reporting Person in the open market or in privately negotiated transactions (which may be with the Issuer or with third parties) on such terms and at …The first part of Item 4 of the SCHEDULE 13D filed 2025-10-29; the filing has the rest
Craig Shore
Item 3 above is hereby incorporated into this Item 4 by reference. As of the date hereof, the Reporting Person in his individual capacity does not have any present plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D. The Reporting Person may, at any time and from time to time, (i) review or reconsider his position in the Issuer or change his purpose or formulate plans or proposals with respect thereto or (ii) propose or consider one or more of the actions described in clauses (a) through (j) of Item 4 to Schedule 13D. From time to time, the Reporting Person may also acquire beneficial ownership of additional Shares or other securities of the Issuer, or dispose of some or all of the Shares beneficially owned by the Reporting Person in the open market or in privately negotiated transactions on such terms and at such times as the Reporting Person may deem advisable.Item 4 of the SCHEDULE 13D/A filed 2025-10-29
Marvin Slosman
Item 3 above is hereby incorporated into this Item 4 by reference. The Reporting Person serves as an executive officer of the Issuer and, in such capacity, may be involved in reviewing transactions involving the Issuer and may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. As of the date hereof, the Reporting Person in his individual capacity does not have any present plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D. The Reporting Person may, at any time and from time to time, (i) review or reconsider his position in the Issuer or change his purpose or formulate plans or proposals with respect thereto or (ii) propose or consider one or more of the actions described in clauses (a) through (j) of Item 4 to Schedule 13D. From time to time, the Reporting Person may also acquire beneficial ownership of additional Shares or other securities of the Issuer as compensation from the Issuer, by purchase or otherwise, including, including, but not limited to, awards of restricted Shares, options to purchase Shares, and restricted stock units for Shares, or dispose of some or all of the Shares beneficially owned by the Reporting Person in the open market or in privately negotiated transactions (which may be with the Issuer or with third parties) on such terms and at …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-24; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-06 | Velan Capital Master Fund LP | 5.1% | SCHEDULE 13G |
| 2025-08-11 | Rosalind Advisors, Inc. | 9.4% | SCHEDULE 13G/A |
| 2025-08-11 | Rosalind Advisors, Inc. | 9.4% | SCHEDULE 13G/A |
| 2025-08-11 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2025-10-29 | Michael A. Lawless | 8.6% | SCHEDULE 13D |
| 2025-10-29 | Craig Shore | 3.5% | SCHEDULE 13D/A |
| 2025-11-07 | Aberdeen Group plc | 5.95% | SCHEDULE 13G |
| 2025-11-14 | Marshall Wace, Llp | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Parkman Healthcare Partners LLC | 5.8% | SCHEDULE 13G |
| 2025-11-14 | OrbiMed Advisors LLC | 4.1% | SCHEDULE 13G/A |
| 2025-11-14 | Nantahala Capital Partners Limited Partnership | 5.68% | SCHEDULE 13G/A |
| 2025-11-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-02 | Aberdeen Group plc | 7.49% | SCHEDULE 13G/A |
| 2026-02-11 | Rosalind Advisors, Inc. | 9.2% | SCHEDULE 13G/A |
| 2026-02-17 | Orbimed Advisors LLC | 7.4% | SCHEDULE 13G |
| 2026-04-24 | Marvin Slosman | 5.18% | SCHEDULE 13D |
| 2026-05-15 | Velan Capital Master Fund LP | 4.99% | SCHEDULE 13G/A |
| 2026-05-15 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for InspireMD, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.
